SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
143 hedge funds and large institutions have $467M invested in SANGAMO THERAPEUTICS INC in 2017 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 42 increasing their positions, 34 reducing their positions, and 13 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
192% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 13
94% more capital invested
Capital invested by funds: $241M → $467M (+$226M)
43% more call options, than puts
Call options by funds: $13.2M | Put options by funds: $9.25M
24% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 34
21% more funds holding
Funds holding: 118 → 143 (+25)
14.47% more ownership
Funds ownership: 59.26% → 73.73% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$16.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$8.38M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$8.02M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.42M |
| 5 |
D.E. Shaw & Co
New York
|
+$5.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Credit Agricole
Montrouge Cedex,
France
|
-$23M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$2.68M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$2.09M |
| 4 |
CCI
Columbus Circle Investors
|
-$1.85M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.59M |
SGMO Hedge Fund Activity: Q2 2017 in Review
143 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q2 2017, worth a combined $467M — up 94% from $241M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new SGMO positions and 13 closed out — a net gain of 25 holders — while 42 added to existing stakes and 34 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $16.5M. The largest seller was Credit Agricole, exiting entirely with an estimated $23M sold.
- 143 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q2 2017, up from 118 in Q1 2017.
- Funds reported $467M of SANGAMO THERAPEUTICS INC stock for Q2 2017, up 94% quarter-over-quarter.
- 38 funds opened new SANGAMO THERAPEUTICS INC positions in Q2 2017 and 13 closed out, a net change of +25 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q2 2017 was EcoR1 Capital, an estimated $16.5M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q2 2017 was Credit Agricole, an estimated $23M sold.
Based on aggregated 13F filings for Q2 2017.